Publications by Trine Folseraas

57 publications found

Publications 2024

  1. Grimsrud MM, Forster M, Goeppert B, Hemmrich-Stanisak G, Sax I, Grzyb K, Braadland PR, Charbel A, Metzger C, Albrecht T, Steiert TA, Schlesner M, Manns MP, Vogel A, Yaqub S, Karlsen TH, Schirmacher P, Boberg KM, Franke A, Roessler S, Folseraas T (2024)
    Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis
    Hepatol Commun, 8 (7)
    DOI 10.1097/HC9.0000000000000461, PubMed 38967597
  2. Poch T, Bahn J, Casar C, Krause J, Evangelakos I, Gilladi H, Kunzmann LK, Laschtowitz A, Iuso N, Schäfer AM, Liebig LA, Steinmann S, Sebode M, Folseraas T, Engesæter LK, Karlsen TH, Franke A, Hubner N, Schlein C, Galun E, Huber S, Lohse AW, Gagliani N, Schwinge D, Schramm C (2024)
    Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis
    Cell Rep Med, 5 (7), 101620
    DOI 10.1016/j.xcrm.2024.101620, PubMed 38901430
  3. van Keulen AM, Buettner S, Olthof PB, Klümpen HJ, Erdmann JI, Izquierdo-Sanchez L, Banales JM, Goeppert B, Roessler S, Zieniewicz K, Lamarca A, Valle JW, La Casta A, Hoogwater FJH, Donadon M, Scheiter A, Marzioni M, Adeva J, Kiudeliene E, Fernández JMU, Vidili G, Mocan T, Fabris L, Krawczyk M, Folseraas T et al. (2024)
    Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
    Ann Surg Oncol, 31 (10), 6495-6503
    DOI 10.1245/s10434-024-15582-5, PubMed 38896226

Publications 2023

  1. Braadland PR, Bergquist A, Kummen M, Bossen L, Engesæter LK, Reims HM, Björk I, Grzyb K, Abildgaard A, Småstuen MC, Folseraas T, Trøseid M, Ulvik A, Ueland PM, Melum E, Line PD, Høivik ML, Grønbæk H, Karlsen TH, Vesterhus M, Hov JR (2023)
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation
    J Hepatol, 79 (4), 955-966
    DOI 10.1016/j.jhep.2023.05.038, PubMed 37328069
  2. De Muynck K, Heyerick L, De Ponti FF, Vanderborght B, Meese T, Van Campenhout S, Baudonck L, Gijbels E, Rodrigues PM, Banales JM, Vesterhuus M, Folseraas T, Scott CL, Vinken M, Van der Linden M, Hoorens A, Van Dorpe J, Lefere S, Geerts A, Van Nieuwerburgh F, Verhelst X, Van Vlierberghe H, Devisscher L (2023)
    Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis
    Hepatology, 79 (2), 269-288
    DOI 10.1097/HEP.0000000000000557, PubMed 37535809
  3. Grant CW, Juran BD, Ali AH, Schlicht EM, Bianchi JK, Hu X, Liang Y, Jarrell Z, Liu KH, Go YM, Jones DP, Walker DI, Miller GW, Folseraas T, Karlsen TH, LaRusso NF, Gores GJ, Athreya AP, Lazaridis KN (2023)
    Environmental chemicals and endogenous metabolites in bile of USA and Norway patients with primary sclerosing cholangitis
    Exposome, 3 (1), osac011
    DOI 10.1093/exposome/osac011, PubMed 36687160
  4. Han Y, Byun J, Zhu C, Sun R, Roh JY, Cordell HJ, Lee HS, Shaw VR, Kang SW, Razjouyan J, Cooley MA, Hassan MM, Siminovitch KA, Folseraas T, Ellinghaus D, Bergquist A, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, International PSC Study Group, McGlynn KA, Roberts LR, Amos CI (2023)
    Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis
    Nat Commun, 14 (1), 1069
    DOI 10.1038/s41467-023-36678-8, PubMed 36828809
  5. Helgadottir H, Folseraas T, Kemmerich G, Aabakken L, Jørgensen KK, Vesterhus M (2023)
    [Primary sclerosing cholangitis]
    Tidsskr Nor Laegeforen, 143 (17)
    DOI 10.4045/tidsskr.23.0156, PubMed 37987062
  6. Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, Schramm C, Arbelaiz A, O'Rourke CJ, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Agüero R, Dill MT, Lamarca A, Valle JW, Macias RIR, Izquierdo-Sanchez L, Pérez Castaño Y, Caballero-Camino FJ, Riaño I, Krawczyk M, Ibarra C, Bustamante J et al. (2023)
    Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
    J Hepatol, 79 (1), 93-108
    DOI 10.1016/j.jhep.2023.02.027, PubMed 36868481
  7. Mikalsen IM, Breder S, Medhus AW, Folseraas T, Aabakken L, Ånonsen KV (2023)
    ERCP for the initial management of malignant biliary obstruction - real world data on 596 procedures
    Scand J Gastroenterol, 59 (3), 369-377
    DOI 10.1080/00365521.2023.2282375, PubMed 37994406
  8. Steiert TA, Parra G, Gut M, Arnold N, Trotta JR, Tonda R, Moussy A, Gerber Z, Abuja PM, Zatloukal K, Röcken C, Folseraas T, Grimsrud MM, Vogel A, Goeppert B, Roessler S, Hinz S, Schafmayer C, Rosenstiel P, Deleuze JF, Gut IG, Franke A, Forster M (2023)
    A critical spotlight on the paradigms of FFPE-DNA sequencing
    Nucleic Acids Res, 51 (14), 7143-7162
    DOI 10.1093/nar/gkad519, PubMed 37351572
  9. Wacker EM, Uellendahl-Werth F, Bej S, Wolkenhauer O, Vesterhus M, Lieb W, Franke A, Karlsen TH, Folseraas T, Ellinghaus D (2023)
    Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis
    JHEP Rep, 6 (2), 100988
    DOI 10.1016/j.jhepr.2023.100988, PubMed 38304234
  10. Yaqub S, Bjørk I, Sugulle M, Folseraas T (2023)
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia
    Lancet, 402 (10403), e10
    DOI 10.1016/S0140-6736(23)01606-9, PubMed 37633669

Publications 2022

  1. Degenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, ElAbd H, Rühlemann MC, Arora J, Özer O, Lenning OB, Myhre R, Vadla MS, Wacker EM, Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-Fernandez AE, Blanco-Grau A, Mantovani A, Zanella A et al. (2022)
    Detailed stratified GWAS analysis for severe COVID-19 in four European populations
    Hum Mol Genet, 31 (23), 3945-3966
    DOI 10.1093/hmg/ddac158, PubMed 35848942
  2. Eliasson J, Lo B, Schramm C, Chazouilleres O, Folseraas T, Beuers U, Ytting H (2022)
    Survey uncovering variations in the management of primary sclerosing cholangitis across Europe
    JHEP Rep, 4 (11), 100553
    DOI 10.1016/j.jhepr.2022.100553, PubMed 36164416
  3. Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, Adeva J, Vogel A, Lleo A, Fabris L, Ponz-Sarvise M, Brustia R, Cardinale V, Braconi C, Vidili G, Jamieson NB, Macias RI, Jonas JP, Marzioni M, Hołówko W, Folseraas T, Kupčinskas J, Sparchez Z, Krawczyk M, Krupa Ł et al. (2022)
    Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
    J Hepatol, 76 (5), 1109-1121
    DOI 10.1016/j.jhep.2021.12.010, PubMed 35167909
  4. Lei L, Bruneau A, El Mourabit H, Guégan J, Folseraas T, Lemoinne S, Karlsen TH, Hoareau B, Morichon R, Gonzalez-Sanchez E, Goumard C, Ratziu V, Charbord P, Gautheron J, Tacke F, Jaffredo T, Cadoret A, Housset C (2022)
    Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis
    Hepatology, 76 (5), 1360-1375
    DOI 10.1002/hep.32456, PubMed 35278227
  5. Nooijen LE, Banales JM, de Boer MT, Braconi C, Folseraas T, Forner A, Holowko W, Hoogwater FJH, Klümpen HJ, Groot Koerkamp B, Lamarca A, La Casta A, López-López F, Izquierdo-Sánchez L, Scheiter A, Utpatel K, Swijnenburg RJ, Kazemier G, Erdmann JI,   ENSCCA Group (2022)
    Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry
    Cancers (Basel), 14 (10)
    DOI 10.3390/cancers14102389, PubMed 35625993
  6. Singh Y, Jons WA, Eaton JE, Vesterhus M, Karlsen T, Bjoerk I, Abildgaard A, Jorgensen KK, Folseraas T, Little D, Gulamhusein AF, Petrovic K, Negard A, Conte GM, Sobek JD, Jagtap J, Venkatesh SK, Gores GJ, LaRusso NF, Lazaridis KN, Erickson BJ (2022)
    Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis
    Eur Radiol Exp, 6 (1), 58
    DOI 10.1186/s41747-022-00312-x, PubMed 36396865
  7. Uellendahl-Werth F, Maj C, Borisov O, Juzenas S, Wacker EM, Jørgensen IF, Steiert TA, Bej S, Krawitz P, Hoffmann P, Schramm C, Wolkenhauer O, Banasik K, Brunak S, Schreiber S, Karlsen TH, Degenhardt F, Nöthen M, Franke A, Folseraas T, Ellinghaus D (2022)
    Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
    Commun Biol, 5 (1), 80
    DOI 10.1038/s42003-022-03031-6, PubMed 35058554
  8. Yu J, Refsum E, Helsingen LM, Folseraas T, Ploner A, Wieszczy P, Barua I, Jodal HC, Melum E, Løberg M, Blom J, Bretthauer M, Adami HO, Kalager M, Ye W (2022)
    Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study
    United European Gastroenterol J, 10 (2), 212-224
    DOI 10.1002/ueg2.12204, PubMed 35107865

Publications 2021

  1. Aune D, Sen A, Norat T, Riboli E, Folseraas T (2021)
    Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies
    Sci Rep, 11 (1), 10646
    DOI 10.1038/s41598-021-90175-w, PubMed 34017024
  2. Dhillon AK, Rupp C, Bergquist A, Voitl R, Folseraas T, Trøseid M, Midttun Ø, Ueland PM, Karlsen TH, Vesterhus M, Kummen M, Hov JR (2021)
    Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis
    Scand J Gastroenterol, 56 (4), 443-452
    DOI 10.1080/00365521.2021.1880627, PubMed 33583308
  3. Fossdal G, Mjelle AB, Wiencke K, Bjørk I, Gilja OH, Folseraas T, Karlsen TH, Rosenberg W, Giil LM, Vesterhus M (2021)
    Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF
    JHEP Rep, 3 (5), 100328
    DOI 10.1016/j.jhepr.2021.100328, PubMed 34485881
  4. Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RI, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW (2021)
    REPLY
    Hepatology, 74 (4), 2319-2321
    DOI 10.1002/hep.31904, PubMed 33998692
  5. Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW (2021)
    REPLY
    Hepatology, 74 (2), 1129-1131
    DOI 10.1002/hep.31740, PubMed 33550618
  6. Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW (2021)
    Letter to the Editor: Does Multiple Intrahepatic Cholangiocarcinoma Worsen Prognosis as "M1" Stage? REPLY
    Hepatology, 74 (2), 1129-1131
    DOI 10.1002/hep.31740
  7. Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW, Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) (2021)
    Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
    Hepatology, 73 (6), 2311-2325
    DOI 10.1002/hep.31598, PubMed 33073396
  8. Mousa OY, Juran BD, McCauley BM, Vesterhus MN, Folseraas T, Turgeon CT, Ali AH, Schlicht EM, Atkinson EJ, Hu C, Harnois D, Carey EJ, Gossard AA, Oglesbee D, Eaton JE, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN (2021)
    Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation
    Hepatology, 74 (1), 281-295
    DOI 10.1002/hep.31652, PubMed 33226645
  9. Vedeld HM, Grimsrud MM, Andresen K, Pharo HD, von Seth E, Karlsen TH, Honne H, Paulsen V, Färkkilä MA, Bergquist A, Jeanmougin M, Aabakken L, Boberg KM, Folseraas T, Lind GE (2021)
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile
    Hepatology, 75 (1), 59-73
    DOI 10.1002/hep.32125, PubMed 34435693
  10. Vesterhus M, Wiencke K, Haukeland JW, Frigstad SO, Karlsen LN, Jørgensen KK, Folseraas T (2021)
    [Diagnosis and treatment of autoimmune hepatitis]
    Tidsskr Nor Laegeforen, 141 (10)
    DOI 10.4045/tidsskr.20.1045, PubMed 34182737

Publications 2020

  1. Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM et al. (2020)
    Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
    Hepatology, 72 (4), 1253-1266
    DOI 10.1002/hep.31110, PubMed 31925805
  2. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F, Kässens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE et al. (2020)
    Genomewide Association Study of Severe Covid-19 with Respiratory Failure
    N Engl J Med, 383 (16), 1522-1534
    DOI 10.1056/NEJMoa2020283, PubMed 32558485
  3. Vedeld HM, Folseraas T, Lind GE (2020)
    Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers
    JHEP Rep, 2 (5), 100143
    DOI 10.1016/j.jhepr.2020.100143, PubMed 32939446

Publications 2019

  1. Carpino G, Cardinale V, Folseraas T, Overi D, Grzyb K, Costantini D, Berloco PB, Di Matteo S, Karlsen TH, Alvaro D, Gaudio E (2019)
    Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis
    Hepatology, 69 (2), 622-638
    DOI 10.1002/hep.30210, PubMed 30102768
  2. Grimsrud MM, Folseraas T (2019)
    Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis
    Liver Int, 39 (12), 2230-2237
    DOI 10.1111/liv.14180, PubMed 31216595

Publications 2018

  1. Thorgersen EB, Melum E, Folseraas T, Larsen SG, Line PD (2018)
    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report
    World J Surg Oncol, 16 (1), 180
    DOI 10.1186/s12957-018-1482-7, PubMed 30185175

Publications 2017

  1. Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J et al. (2017)
    Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
    Gut, 67 (8), 1517-1524
    DOI 10.1136/gutjnl-2016-313598, PubMed 28779025
  2. Carpino G, Cardinale V, Folseraas T, Overi D, Floreani A, Franchitto A, Onori P, Cazzagon N, Berloco PB, Karlsen TH, Alvaro D, Gaudio E (2017)
    Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis
    Am J Pathol, 188 (3), 627-639
    DOI 10.1016/j.ajpath.2017.11.010, PubMed 29248458
  3. Chung BK, Karlsen TH, Folseraas T (2017)
    Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma
    Biochim Biophys Acta Mol Basis Dis, 1864 (4 Pt B), 1390-1400
    DOI 10.1016/j.bbadis.2017.08.020, PubMed 28844951
  4. Henriksen EKK, Viken MK, Wittig M, Holm K, Folseraas T, Mucha S, Melum E, Hov JR, Lazaridis KN, Juran BD, Chazouillères O, Färkkilä M, Gotthardt DN, Invernizzi P, Carbone M, Hirschfield GM, Rushbrook SM, Goode E, UK-PSC Consortium, Ponsioen CY, Weersma RK, Eksteen B, Yimam KK, Gordon SC, Goldberg D et al. (2017)
    HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry
    HLA, 90 (4), 228-233
    DOI 10.1111/tan.13076, PubMed 28695657
  5. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017)
    Primary sclerosing cholangitis - a comprehensive review
    J Hepatol, 67 (6), 1298-1323
    DOI 10.1016/j.jhep.2017.07.022, PubMed 28802875

Publications 2016

  1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D (2016)
    Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
    Nat Rev Gastroenterol Hepatol, 13 (5), 261-80
    DOI 10.1038/nrgastro.2016.51, PubMed 27095655
  2. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hübenthal M, Folseraas T, Wang Y, Esko T, Metspalu A, Westra HJ, Franke L, Pers TH, Weersma RK, Collij V, D'Amato M, Halfvarson J, Jensen AB, Lieb W, Degenhardt F, Forstner AJ et al. (2016)
    Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
    Nat Genet, 48 (5), 510-8
    DOI 10.1038/ng.3528, PubMed 26974007
  3. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F et al. (2016)
    Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
    Nat Genet, 49 (2), 269-273
    DOI 10.1038/ng.3745, PubMed 27992413

Publications 2015

  1. Folseraas T, Boberg KM (2015)
    Cancer Risk and Surveillance in Primary Sclerosing Cholangitis
    Clin Liver Dis, 20 (1), 79-98
    DOI 10.1016/j.cld.2015.08.014, PubMed 26593292
  2. Folseraas T, Liaskou E, Anderson CA, Karlsen TH (2015)
    Genetics in PSC: what do the "risk genes" teach us?
    Clin Rev Allergy Immunol, 48 (2-3), 154-64
    DOI 10.1007/s12016-014-8417-z, PubMed 24736995
  3. Li J, Jørgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, Pandey R, Salzer U, Schmidt RE, Perez E, Resnick E, Goldacker S, Buchta M, Witte T, Padyukov L, Videm V, Folseraas T, Atschekzei F, Elder JT, Nair RP, Winkelmann J, Gieger C, Nöthen MM, Büning C, Brand S et al. (2015)
    Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells
    Nat Commun, 6, 6804
    DOI 10.1038/ncomms7804, PubMed 25891430
  4. Wannhoff A, Folseraas T, Brune M, Rupp C, Friedrich K, Knierim J, Weiss KH, Sauer P, Flechtenmacher C, Schirmacher P, Stremmel W, Hov JR, Gotthardt DN (2015)
    A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis
    United European Gastroenterol J, 4 (1), 84-91
    DOI 10.1177/2050640615581577, PubMed 26966527

Publications 2014

  1. Rupp C, Friedrich K, Folseraas T, Wannhoff A, Bode KA, Weiss KH, Schirmacher P, Sauer P, Stremmel W, Gotthardt DN (2014)
    Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis
    Aliment Pharmacol Ther, 39 (8), 873-82
    DOI 10.1111/apt.12663, PubMed 24612312

Publications 2013

  1. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weismüller TJ, Schramm C, Wittig M, Bergquist A, Björnsson E, Marschall HU, Vatn M, Teufel A, Rust C, Gieger C, Wichmann HE, Runz H, Sterneck M, Rupp C, Braun F, Weersma RK et al. (2013)
    Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4
    Hepatology, 58 (3), 1074-83
    DOI 10.1002/hep.25977, PubMed 22821403
  2. Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S et al. (2013)
    Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
    Nat Genet, 45 (6), 670-5
    DOI 10.1038/ng.2616, PubMed 23603763
  3. Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN (2013)
    FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis
    J Hepatol, 59 (6), 1278-84
    DOI 10.1016/j.jhep.2013.08.005, PubMed 23958938

Publications 2012

  1. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, Laerdahl JK, Ellinghaus D, Schramm C, Weismüller TJ, Gotthardt DN, Hov JR, Clausen OP, Weersma RK, Janse M, Boberg KM, Björnsson E, Marschall HU, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann HE et al. (2012)
    Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci
    J Hepatol, 57 (2), 366-75
    DOI 10.1016/j.jhep.2012.03.031, PubMed 22521342

Publications 2011

  1. Folseraas T, Karlsen TH (2011)
    To MMP or not to MMP: a role for matrix metalloproteinase 3 in primary sclerosing cholangitis?
    Liver Int, 31 (6), 751-4
    DOI 10.1111/j.1478-3231.2011.02471.x, PubMed 21645205
  2. Folseraas T, Melum E, Franke A, Karlsen TH (2011)
    Genetics in primary sclerosing cholangitis
    Best Pract Res Clin Gastroenterol, 25 (6), 713-26
    DOI 10.1016/j.bpg.2011.09.010, PubMed 22117637
  3. Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismüller TJ, Wedemeyer J, Schramm C, Sterneck M, Günther R, Braun F et al. (2011)
    Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9
    Hepatology, 53 (6), 1977-85
    DOI 10.1002/hep.24307, PubMed 21425313

 
Page visits: 10889